Family Medicine Doctors in Smethport, PA Accepting Medicare
3 Family Medicine doctors found. Showing 1 - 3
 Fayyaz Qadir, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 Franklin St., Smethport, PA 16749 Phone: 814-887-5655 Fax: 814-887-1911 |
Dr. Cory Michael Mathias, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 Franklin St, Smethport, PA 16749 Phone: 814-887-5655 Fax: 814-887-1911 |
Renato Domenack Casas, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 406 Franklin St, Smethport, PA 16749 Phone: 814-362-8356 |
News Archive
Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients
Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.
Genomic component playing key role in promoting breast cancer progression discovered
Life Technologies Corporation today announced that its scientists have teamed with researchers from Stanford University School of Medicine, and other institutions to discover a genomic component that plays a key role in promoting breast cancer progression. A study published today in the journal Nature details how levels of a specific kind of non-coding RNA molecule in primary breast tumors regulate metastasis and tumor invasiveness and may be an important target for cancer diagnosis and therapy.
Glaukos receives FDA approval for iStent Trabecular Micro-Bypass Stent System
Today, the iStent Trabecular Micro-Bypass Stent System, Model GTS100R/L, was approved by the U.S. Food and Drug Administration. This is the first device approved for use in combination with cataract surgery to reduce pressure inside the eye (intraocular pressure) in adult patients with mild or moderate open-angle glaucoma and a cataract who are currently being treated with medication to reduce intraocular pressure.
FIOCRUZ receives Brazil's Anvisa regulatory approval to market Chembio's Dual Path Platform HIV 1/2 rapid test
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 1 days ago